GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE
Methods and compositions including granulin/epithelin modules (GEMs) or combinations thereof suitable for treating neurodegenerative diseases. Also disclosed are methods of treatment of neurodegenerative diseases, such as methods of administering therapeutic recombinant GEM proteins or gene therapies for delivering recombinant GEM gene products.
1 . A recombinant polypeptide or combination of multiple recombinant polypeptides, comprising two to six granulin/epithelin modules (GEMs).
2 . The recombinant polypeptide or combination according to claim 1 , comprising two to six granulin/epithelin modules (GEMs), comprising GEM E, and additionally one or more of GEM F, GEM B, GEM C and GEM D.
3 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) E, and additionally GEM F.
4 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) E, and additionally GEM C.
5 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) E, and additionally GEM B.
6 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) E, and additionally GEM F and GEM D.
7 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) E, and additionally GEM F, GEM D and GEM C.
8 . The recombinant polypeptide or combination according to claim 1 , comprising two to six granulin/epithelin modules (GEMs), comprising GEM F, and additionally one or more of GEM A, GEM B, GEM E, GEM C and GEM D.
9 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) F, and additionally GEM B.
10 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) F, and additionally GEM A.
11 . The recombinant polypeptide or combination according to claim 1 , comprising granulin/epithelin module (GEM) F, and additionally GEM D.
12 . The recombinant polypeptide or combination according to claim 1 , comprising a signal sequence positioned N-terminally of the GEMs.
13 . The recombinant polypeptide or combination according to claim 1 , comprising one or more linker (leader) sequences positioned N-terminally of and/or between the GEMs.
14 . The recombinant polypeptide or combination according to claim 1 , wherein the polypeptide comprises or consists of a mixed portion of a full-length PGRN sequence according to SEQ ID NO 1, and/or does not consist of the full-length PGRN sequence according to SEQ ID NO 1.
15 . The recombinant polypeptide or combination according to claim 1 , wherein:
a. GEM E comprises or consists of SEQ ID NO 5,
b. GEM F comprises or consists of SEQ ID NO 2,
c. GEM C comprises or consists of SEQ ID NO 4,
d. GEM D comprises or consists of SEQ ID NO 8,
e. GEM A comprises or consists of SEQ ID NO 7, and/or
f. GEM B comprises or consists of SEQ ID NO 3.
16 . The recombinant polypeptide or combination according to claim 1 ,
a. comprising a signal sequence positioned N-terminally of the GEMs, wherein the signal sequence comprises or consists of SEQ ID NO 26, and/or
b. comprising one or more linker (leader) sequences positioned N-terminally of and/or between the GEMs, wherein the linker sequence comprises or consists of one or more linker sequences of or from within a sequence according to SEQ ID NO 27-35, and/or
c. comprising or consisting of one or more of SEQ ID NO 27-35.
17 . (canceled)
18 . (canceled)
19 . A combination of multiple recombinant polypeptides, said combination comprising the two to six granulin/epithelin modules (GEMs) according to claim 1 , comprising GEM E, and additionally one or more of GEM B, GEM F, GEM C and GEM D, and/or comprising two to six granulin/epithelin modules (GEMs), comprising GEM F, and additionally one or more of GEM B, GEM E, GEM A and GEM D.
20 . A nucleic acid molecule encoding the recombinant polypeptide or combination of multiple recombinant polypeptides according to claim 1 .
21 . The nucleic acid molecule according to claim 20 , present as a combination of multiple nucleic acid molecules, each encoding one or more of a combination of recombinant polypeptides.
22 . The nucleic acid molecule according to claim 20 , in the form of a vector configured to express the recombinant polypeptide after administration to a subject.
23 . The nucleic acid molecule according to claim 20 , wherein the vector is selected from the group consisting of an adenovirus, adeno-associated virus, lentivirus and baculovirus.
24 . The nucleic acid molecule according to claim 20 , wherein said molecule encodes multiple GEMs configured for expression as a polycistronic mRNA, wherein said GEMs are encoded by a single nucleic acid molecule and configured for cleavage post-transcription and/or post-translation, and/or wherein the polycistronic mRNA comprises multiple internal ribosome entry sites (IRES), enabling expression of multiple distinct and soluble GEM polypeptides.
25 . (canceled)
26 . A pharmaceutical composition comprising the recombinant polypeptide or combination according to claim 1 , with a pharmaceutically acceptable excipient.
27 . A method of treating a neurodegenerative disease in a subject, the method comprising administering a therapeutically effective amount of the polypeptide or combination according to claim 1 to a subject in need thereof, optionally in the form of a-nucleic acid molecule encoding the recombinant polypeptide or combination of multiple recombinant polypeptides according to claim 1 and/or a pharmaceutical composition comprising the recombinant polypeptide or combination according to claim 1 .
28 . The method according to claim 27 , wherein the neurodegenerative disease is selected from the group consisting of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Spinal Muscular Atrophy (SMA), Alzheimer's Disease (AD) and Parkinson's Disease (PD).
29 . The method according to claim 27 , wherein the neurodegenerative disease is selected from a disease associated with aberrant lysosomal function.